ARRHYTHMIA RESEARCH TECHNOLOGY, INC. Announces a 5-Year Supply Agreement.

FITCHBURG, Mass. -- Arrhythmia Research Technology, Inc. (AMEX: HRT) announced that its wholly owned subsidiary Micron Products Inc. ("Micron"), has entered into a five-year supply agreement with ConforMIS, Inc. Micron, through it's Micron Integrated Technologies and Leominster Tool divisions, will provide manufacturing services for the ConforMIS Knee Interpositional Device, the iForma[TM], for use in the treatment of patients with early to moderate osteoarthritis.

ConforMIS develops unique, patient-specific implants capable of re-establishing normal articular alignment and relieving pain in patients with osteoarthritis of the knee. Each device is manufactured to conform to an individual patient's unique anatomy, allowing for maximum tissue preservation and minimal surgical trauma. Preserving bone stock is especially important to younger and more active individuals.

The ConforMIS iForma is a small, lightweight, personalized metal implant designed for patients with early to moderate osteoarthritis in either the medial or lateral compartment of the knee. It fits into the affected compartment between the femur (thigh bone) and tibia (shin bone) and helps fill the lost cartilage, restore the knee's proper alignment, and prevent painful rubbing of the bones during ambulation. Its precise fit to the structure of the joint allows the surgeon to easily insert the device through a small incision, achieving functional fixation without the need for cement or screws. The iForma allows patients to return to light to moderate physical activities and allows for easy revision to other procedures in the future, if necessary.

James E. Rouse, President and CEO of Arrhythmia Research Technology, Inc., commented, "We are very pleased to have been chosen by ConforMIS as the turn-key manufacturer of the iForma. This opportunity to augment our manufacturing capabilities to include finished medical devices represents just one success in the continuing efforts of our business development team to expand and diversify our business. The agreement calls for the iForma to be the first in a series of ConforMIS products to be manufactured by Micron and its divisions as we expand upon the close working relationship that has developed between our two companies. Micron's expansion into medical device manufacturing for an OEM customer such as ConforMIS complements our proven capability as a high quality manufacturer of components for medical products."

Patrick Hess, Ph.D, CEO of ConforMIS commented, "Micron provides us with the manufacturing and service excellence to continue building our unique value proposition to our customers. We evaluated a number of manufacturers and found Micron's flexible manufacturing operations and commitment to helping us scale over time to be unique. Given our rapid growth and patient-specific manufacturing process, we were pleased to find a manufacturer who demonstrated a willingness to work with us as partners."

About Arrhythmia Research Technology, Inc.

ART, through Micron, manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's NEM division manufactures custom injection molded products for medical, electronic, industrial and consumer applications. Micron's MIT division provides end- to- end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. Micron's Leominster Tool division provides high end mold design, manufacturing and precision machining for various industries. The Company's products also include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal hearth arrhythmias.

For more information please check our websites:

    http://www.arthrt.com            http://www.micronproducts.com
    http://www.leominstertool.com    http://www.newenglandmolders.com
    http://www.micronintegrated.com

About ConforMIS, Inc.

ConforMIS, Inc., located outside Boston, MA, is a privately held medical device company incorporated in 2004.

Its mission is to provide best-in-class, minimally invasive implants for orthopedics and sports medicine through the use of its proprietary iFit Technology[TM]. The iFit Technology is a patent-protected, software-enabled process for converting CT and MR imaging data into conforming, patient-specific implants. This 'image-to-implant' technology allows for precisely sized and shaped implants that reduce or eliminate the need for cartilage removal or bone resection and radically simplify the surgical procedure.

With over 100 allowed and pending patent applications, ConforMIS has developed a portfolio of diverse, integrated intellectual property and know-how spanning multiple aspects of musculoskeletal medicine including:

* Imaging Software

* Image Processing

* Implant Design

* Surgical Instrumentation

* Guidance Systems

To date, the company has developed a comprehensive line of minimally invasive bone and cartilage preserving knee implants for all stages of osteoarthritis with regulatory clearance from the US FDA and CE Mark in Europe.

For more information please check our website: http://www.conformis.com.

Note Regarding Forward Looking Statements

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, changing economic conditions in developing countries, and an inability to arrange additional debt or equity financing. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006.